Canvas Wealth Advisors LLC Decreases Stock Position in Qiagen N.V. (NYSE:QGEN)

Canvas Wealth Advisors LLC trimmed its position in Qiagen N.V. (NYSE:QGEN - Free Report) by 19.3% during the first quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 32,638 shares of the company's stock after selling 7,788 shares during the period. Canvas Wealth Advisors LLC's holdings in Qiagen were worth $1,382,000 at the end of the most recent reporting period.

Several other hedge funds also recently modified their holdings of the company. Blue Trust Inc. lifted its stake in shares of Qiagen by 30.5% during the 1st quarter. Blue Trust Inc. now owns 13,519 shares of the company's stock worth $543,000 after purchasing an additional 3,157 shares during the period. Bank Pictet & Cie Europe AG acquired a new position in Qiagen in the first quarter valued at $669,000. Exchange Traded Concepts LLC increased its stake in Qiagen by 2.3% in the first quarter. Exchange Traded Concepts LLC now owns 17,825 shares of the company's stock valued at $716,000 after purchasing an additional 395 shares during the last quarter. GAMMA Investing LLC lifted its position in Qiagen by 93.9% during the first quarter. GAMMA Investing LLC now owns 2,943 shares of the company's stock worth $118,000 after buying an additional 1,425 shares during the period. Finally, Wealth Enhancement Advisory Services LLC acquired a new stake in Qiagen in the 4th quarter worth about $202,000. 70.00% of the stock is owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

QGEN has been the subject of a number of research analyst reports. Wall Street Zen raised shares of Qiagen from a "buy" rating to a "strong-buy" rating in a research note on Thursday, May 15th. Robert W. Baird upped their price target on shares of Qiagen from $42.00 to $43.00 and gave the stock a "neutral" rating in a research report on Monday, April 21st. Redburn Atlantic downgraded shares of Qiagen from a "buy" rating to a "neutral" rating in a research note on Friday, April 4th. Bank of America lifted their price target on shares of Qiagen from $50.00 to $53.00 and gave the company a "buy" rating in a report on Thursday. Finally, Barclays assumed coverage on shares of Qiagen in a research note on Tuesday, June 24th. They set an "overweight" rating and a $55.00 price objective for the company. Seven equities research analysts have rated the stock with a hold rating, three have assigned a buy rating and one has issued a strong buy rating to the stock. According to MarketBeat.com, the company presently has an average rating of "Hold" and an average price target of $49.40.

Qiagen Trading Up 0.6%

QGEN stock traded up $0.30 during midday trading on Monday, reaching $48.07. 747,677 shares of the company's stock traded hands, compared to its average volume of 1,193,598. Qiagen N.V. has a fifty-two week low of $37.63 and a fifty-two week high of $49.30. The business has a 50-day moving average price of $44.21 and a two-hundred day moving average price of $42.50. The company has a market capitalization of $10.69 billion, a P/E ratio of 120.52, a PEG ratio of 2.44 and a beta of 0.67. The company has a debt-to-equity ratio of 0.40, a current ratio of 3.37 and a quick ratio of 2.83.

Qiagen (NYSE:QGEN - Get Free Report) last announced its quarterly earnings results on Wednesday, May 7th. The company reported $0.55 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.50 by $0.05. Qiagen had a return on equity of 14.61% and a net margin of 4.68%. The firm had revenue of $483.46 million during the quarter, compared to the consensus estimate of $465.66 million. During the same period in the prior year, the firm earned $0.44 EPS. The firm's quarterly revenue was up 5.2% compared to the same quarter last year. Equities research analysts forecast that Qiagen N.V. will post 2.26 EPS for the current fiscal year.

Qiagen Company Profile

QIAGEN NV is a holding company, which engages in the provision of Sample to Insight solutions that enable customers to gain valuable molecular insights from samples containing the building blocks of life. The company sample technologies isolate and process DNA, RNA, and proteins from blood, tissue, and other materials.